KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2026)

Moderna (MRNA) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $59.0 million as the latest value for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) rose 51.28% year-over-year to $59.0 million; the TTM value through Mar 2026 reached $235.0 million, up 22.4%, while the annual FY2025 figure was $215.0 million, 13.76% up from the prior year.
  • Depreciation & Amortization (CF) hit $59.0 million in Q1 2026 for Moderna, down from $67.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $249.0 million in Q3 2023 and bottomed at $36.0 million in Q1 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $84.2 million, with a median of $67.0 million recorded in 2025.
  • Year-over-year, Depreciation & Amortization (CF) skyrocketed 426.67% in 2022 and then tumbled 79.12% in 2024.
  • Moderna's Depreciation & Amortization (CF) stood at $80.0 million in 2022, then surged by 152.5% to $202.0 million in 2023, then crashed by 70.3% to $60.0 million in 2024, then rose by 11.67% to $67.0 million in 2025, then fell by 11.94% to $59.0 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $59.0 million, $67.0 million, and $52.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.